Janssen Pharmaceuticals and parent company Johnson & Johnson have a history of settling Risperdal lawsuits. In 2012, J&J agreed to settle 5 Risperdal lawsuits alleging that the drug led to increased breast tissue growth in boys and male adolescents. More than 100 similar claims had been filed against the companies at the time.
Risperdal has been linked to an increased risk of breast tissue growth in boys and male adolescents, a condition called “gynecomastia.” Hundreds of Risperdal gynecomastia lawsuits have been filed since Janssen settled in 2012.
As much as 25% of cases of male breast growth are tied to drugs like the antipsychotic Risperdal. Risperdal has been found to increase levels of a hormone known as prolactin, which can lead to increased breast tissue in boys. The increased levels of prolactin can last for years after use of the medication has stopped.